会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Human prostaglandin FP receptor variants and methods of using same
    • 人类前列腺素FP受体变体及其使用方法
    • US07320871B2
    • 2008-01-22
    • US10620289
    • 2003-07-14
    • Yanbin LiangDavid F. Woodward
    • Yanbin LiangDavid F. Woodward
    • C07K14/705G01N33/566
    • G01N33/88C07K14/72G01N2500/04
    • The invention provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 24, or 25. The invention also provides an isolated polypeptide containing an amino acid sequence having at least 50% amino acid identity with SEQ ID NO: 14 and an amino acid sequence of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 24, or 25, or a conservative variant thereof. The invention further provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, or 12. The invention also provides a method for identifying a compound that modulates a FP receptor variant by contacting an isolated FP receptor variant or a FP receptor variant over-expressed in a genetically engineered cell with a compound and determining the level of an indicator which correlates with modulation of a FP receptor variant, where an alteration in the level of the indicator as compared to a control level indicates that the compound is a compound that modulates the FP receptor variant.
    • 本发明提供了含有SEQ ID NO:17,18,19,20,21,22,23,24或25的氨基酸序列的分离的多肽。本发明还提供了一种分离的多肽,其含有至少具有至少 与SEQ ID NO:14的50%氨基酸同一性和SEQ ID NO:17,18,19,20,21,22,23,24或25的氨基酸序列或其保守变体。 本发明还提供了含有SEQ ID NO:2,4,6,8,10或12的氨基酸序列的分离的多肽。本发明还提供了一种鉴定通过使分离的 FP受体变体或在具有化合物的遗传工程化细胞中过表达的FP受体变体,并确定与FP受体变体的调节相关的指标水平,其中与对照相比,指标水平的改变 水平表示该化合物是调节FP受体变体的化合物。
    • 4. 发明授权
    • Human COX-1 alternatively spliced variants and methods of using same
    • 人类COX-1可变剪接变体及其使用方法
    • US07198928B2
    • 2007-04-03
    • US10663377
    • 2003-09-15
    • Yanbin LiangDavid F. Woodward
    • Yanbin LiangDavid F. Woodward
    • C12N9/02C12N1/20C12N15/70C12P21/06C07H21/04
    • C12N9/0083
    • The invention provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 14, 16, 18, 20, 22 or 24. The invention also provides an isolated polypeptide containing a) an amino acid sequence having at least 50% amino acid identity with SEQ ID NO: 10, and b) an amino acid sequence selected from SEQ ID NOS: 14, 16, 18, 20, 22, or 24; or a conservative variant thereof. The invention further provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 2, 4, 6, or 8. The invention also provides a method for identifying a compound that modulates a COX-1 variant by contacting an isolated COX-1 variant or a COX-1 variant over-expressed in a genetically engineered cell with a compound and determining the level of an indicator which correlates with modulation of a COX-1 variant, where an alteration in the level of the indicator as compared to a control level indicates that the compound is a compound that modulates the COX-1 variant.
    • 本发明提供了含有SEQ ID NO:14,16,18,20,22或24的氨基酸序列的分离的多肽。本发明还提供了分离的多肽,其含有a)具有至少50%氨基酸同一性的氨基酸序列 具有SEQ ID NO:10,和b)选自SEQ ID NO:14,16,18,20,22或24的氨基酸序列; 或其保守变体。 本发明还提供了含有SEQ ID NO:2,4,6或8的氨基酸序列的分离的多肽。本发明还提供了通过使分离的COX-1接触来鉴定调节COX-1变体的化合物的方法 变体或在具有化合物的遗传工程细胞中过表达的COX-1变体,并确定与COX-1变体的调节相关的指标水平,其中与对照相比,指标水平的变化 水平表示该化合物是调节COX-1变体的化合物。
    • 6. 发明申请
    • Human prostaglandin FP receptor variants and methods of using same
    • 人类前列腺素FP受体变体及其使用方法
    • US20060105346A1
    • 2006-05-18
    • US10620289
    • 2003-07-14
    • Yanbin LiangDavid Woodward
    • Yanbin LiangDavid Woodward
    • G01N33/00C12Q1/68C07H21/04C07K14/705C07K16/28
    • G01N33/88C07K14/72G01N2500/04
    • The invention provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 24, or 25. The invention also provides an isolated polypeptide containing an amino acid sequence having at least 50% amino acid identity with SEQ ID NO: 14 and an amino acid sequence of SEQ ID NO: 17, 18, 19, 20, 21, 22, 23, 24, or 25, or a conservative variant thereof. The invention further provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, or 12. The invention also provides a method for identifying a compound that modulates a FP receptor variant by contacting an isolated FP receptor variant or a FP receptor variant over-expressed in a genetically engineered cell with a compound and determining the level of an indicator which correlates with modulation of a FP receptor variant, where an alteration in the level of the indicator as compared to a control level indicates that the compound is a compound that modulates the FP receptor variant.
    • 本发明提供了含有SEQ ID NO:17,18,19,20,21,22,23,24或25的氨基酸序列的分离的多肽。本发明还提供了一种分离的多肽,其含有至少具有至少 与SEQ ID NO:14的50%氨基酸同一性和SEQ ID NO:17,18,19,20,21,22,23,24或25的氨基酸序列或其保守变体。 本发明还提供了含有SEQ ID NO:2,4,6,8,10或12的氨基酸序列的分离的多肽。本发明还提供了一种鉴定通过使分离的 FP受体变体或在具有化合物的遗传工程化细胞中过表达的FP受体变体,并确定与FP受体变体的调节相关的指标水平,其中与对照相比,指标水平的改变 水平表示该化合物是调节FP受体变体的化合物。
    • 7. 发明申请
    • Human COX-1 alternatively spliced variants and methods of using same
    • 人类COX-1可变剪接变体及其使用方法
    • US20050233429A1
    • 2005-10-20
    • US10663377
    • 2003-09-15
    • Yanbin LiangDavid Woodward
    • Yanbin LiangDavid Woodward
    • C07H21/04C07K16/40C12N20060101C12N9/02
    • C12N9/0083
    • The invention provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 14, 16, 18, 20, 22 or 24. The invention also provides an isolated polypeptide containing a) an amino acid sequence having at least 50% amino acid identity with SEQ ID NO: 10, and b) an amino acid sequence selected from SEQ ID NOS: 14, 16, 18, 20, 22, or 24; or a conservative variant thereof. The invention further provides an isolated polypeptide containing the amino acid sequence of SEQ ID NO: 2, 4, 6, or 8. The invention also provides a method for identifying a compound that modulates a COX-1 variant by contacting an isolated COX-1 variant or a COX-1 variant over-expressed in a genetically engineered cell with a compound and determining the level of an indicator which correlates with modulation of a COX-1 variant, where an alteration in the level of the indicator as compared to a control level indicates that the compound is a compound that modulates the COX-1 variant.
    • 本发明提供了含有SEQ ID NO:14,16,18,20,22或24的氨基酸序列的分离的多肽。本发明还提供了分离的多肽,其含有a)具有至少50%氨基酸同一性的氨基酸序列 具有SEQ ID NO:10,和b)选自SEQ ID NO:14,16,18,20,22或24的氨基酸序列; 或其保守变体。 本发明还提供了含有SEQ ID NO:2,4,6或8的氨基酸序列的分离的多肽。本发明还提供了通过使分离的COX-1接触来鉴定调节COX-1变体的化合物的方法 变体或在具有化合物的遗传工程细胞中过表达的COX-1变体,并确定与COX-1变体的调节相关的指标水平,其中与对照相比,指标水平的改变 水平表示该化合物是调节COX-1变体的化合物。